Perrigo gets approval for generic Aldara
ALLEGAN, Mich. The Food and Drug Administration has approved Perrigo’s generic drug for treating skin diseases, the drug maker said Wednesday.
The FDA approved Perrigo’s imiquimod cream in the 5% strength. The drug is a generic version of Graceway Pharmaceuticals’ Aldara.
The drug is used to treat actinic keratoses on the face and scalp, superficial basal cell carcinoma and external genital and perianal warts in patients ages 12 years and older.
Bristol-Myers Squibb to acquire ZymoGenetics
SEATTLE Bristol-Myers Squibb will acquire Seattle-based biotech ZymoGenetics, Bristol said Wednesday.
The New York-based drug maker will acquire ZymoGenetics for $885 million, or $9.75 per share. The boards of both companies approved the deal unanimously.
The buyout gives Bristol ownership of Recothrom, used to control bleeding during surgical procedures, pegylated-interferon lambda, an investigational treatment for hepatitis C in mid-stage clinical trials, and IL-21, a treatment for melanoma also in mid-stage trials.
“The acquisition of ZymoGenetics brings us full ownership of a promising investigational biologic that strengthens our very diversified hepatitis C portfolio,” Bristol CEO Lamberto Andreotti said. “Building on our leadership in virology, we are developing a strong portfolio to help patients with hepatitis C.”
GSK inks deal with Lonza, announces CFO’s exit
LONDON Swiss drug maker Lonza will help British drug maker GlaxoSmithKline manufacture five biotech drugs in early- and mid-stage clinical trials, the two companies said Wednesday.
Lonza will manufacture clinical trial batches of the drugs, all monoclonal antibodies in phase-1 and phase-2 testing, and provide additional access to manufacturing capacity so GSK can fulfill future demands. The two companies said other details of the agreement remain confidential.
“We believe this is a critical step in the ongoing and future success of GSK in biopharmaceuticals,” GSK head of biopharmaceutical research and development Ian Tomlinson said.
Tomlinson said the company’s goal was to have a biopharmaceutical portfolio that consistently exceeded 20% of its research and development pipeline by 2015.
In other news, the company said that CFO and executive director Julian Heslop would retire at the end of March 2011. Goldman Sachs executive Simon Dingemans will be appointed CFO designate and executive director in January.